Jean-Patrice Labautiere
Jean-Patrice Labautiere
Jean-Patrice Labautiere
Biography
Jean-Patrice Labautière advises French and foreign companies, financial institutions and private equity clients on M&A and private equity transactions. He has significant experience in the structuring, negotiation and documentation of complex acquisitions, leveraged buyouts, corporate reorganisations and joint ventures involving the coordination of legal teams from different jurisdictions.
Jean-Patrice advises on all types of corporate transactions in a practical and business-oriented manner.
Prior to joining BCLP, Jean-Patrice was a partner at the Paris office of a leading international U.S. law firm and previously a partner at the Paris office of a ‘Magic Circle’ firm. He is fluent in English, French and Spanish.
Areas of Focus
-
Health & Safety
-
Technology Transactions
-
Entertainment & Media
-
Financial Services
Civic Involvement & Honors
- Nominated by clients “Lawyer of the Year” in Private Equity (Palmarès du Droit 2022).
- Ranked as a “Star” by Acritas and in The Legal 500, and various French legal directories in M&A, Private Equity and for Healthcare transactions.
Admissions
-
England & Wales (Registered Foreign Lawyer)
Related Practice Areas
-
M&A & Corporate Finance
-
Healthcare & Life Sciences
-
Corporate
Experience
-
Represented Vantiva SA (Euronext Paris: VANTI) in relation to the acquisition of the Home Networks division of CommScope (Nasdaq: COMM) in consideration for 25% of the share capital of Vantiva SA
- Represented Technicolor SA in connection with the sale of its Trademark Licensing operations to one of the largest diversified financial institutions for approx. €100 million in cash.
- Represented Eurazeo Healthcare in relation to its investment in Groupe Novair.
- Represented Ipsos in relation to a number of matters, including:
- the acquisition of GfK’s Custom Research Business in 25 countries;
- the creation of Ipsos Partners, a management company with approx. 150 managers of the Ipsos group in the World;
- the acquisition of Synovate from Aegis;
- the acquisition of OTX; and
- the acquisition of MORI.
- Represented bioMérieux in relation to acquisitions and a tripartite joint venture.
- Represented Riverside Europe Partners on number of matters, including:
- working with them and the founders of HRA Pharma in relation to the sale of HRA Pharma to Astorg Partners and Goldman Sachs;
- the acquisition of Soft Medical Europe;
- the sale of Orliman to Magnum Capital; and
- in relation to its investment in HRA Pharma.
- Represented Sanofi Pasteur-MSD in relation to the termination of the joint vaccine activities of Sanofi and Merck in Europe.
- Represented Double A in relation to the sale of DA Alizay to VPK.
- Represented Leading Debt Funds and a Leading Servicer in relation to the acquisition of several NPL Portfolios.
- Represented ABN AMRO in relation to the disposal of its direct assets management business to Candriam.
Related Insights
Apr 04, 2024
Mar 22, 2024
Oct 10, 2023
Apr 20, 2023
Apr 04, 2023
Oct 07, 2022